Other studies in myeloma also showed a combinatory effect with the anti-myeloma agents melphalan, vincristine, etoposide and the topoisomerase II inhibitor doxorubicin.15,27 Topoisomerase IIα is identified as a Cdh1 substrate and both proTAME and knockdown of Cdh1 significantly enhance the sensitivity of cancers cells to topoisomerase II inhibitors.49 Consistent with these findings, proTAME was also found to sensitise all lymphoma cell lines tested to doxorubicin. The gene discussed is CDH1; the disease is lymphoma.